We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.76%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$50M
Cap. Flow
+$37M
Cap. Flow %
11.45%
Top 10 Hldgs %
80.32%
Holding
49
New
10
Increased
8
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.06M
2
ABT icon
Abbott
ABT
+$4.8M
3
MCK icon
McKesson
MCK
+$4.23M
4
BDX icon
Becton Dickinson
BDX
+$3.81M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$7.25M
2
DCGO icon
DocGo
DCGO
+$4.17M
3
VTRS icon
Viatris
VTRS
+$2.39M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.14M
5
RDNT icon
RadNet
RDNT
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 40.41%
2 Consumer Staples 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCGO icon
26
DocGo
DCGO
$61.3M
$1.26M 0.39%
135,000
-475,000
-78% -$4.17M
MDRX
27
CALL
DELISTED
Veradigm Inc. Common Stock
MDRX
$1.26M 0.39%
+100,000
New +$1.21M
SPB icon
28
Spectrum Brands
SPB
$2.08B
$781K 0.24%
+10,000
New +$714K
BIO icon
29
Bio-Rad Laboratories Class A
BIO
$8.74B
$758K 0.23%
2,000
+1,000
+100% +$407K
TECH icon
30
Bio-Techne
TECH
$11.2B
$327K 0.1%
4,000
+3,000
+300% +$241K
OLK
31
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$281K 0.09%
15,000
-13,500
-47% -$279K
SLGC
32
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$254K 0.08%
110,000
-365,000
-77% -$1.03M
SLGC
33
CALL
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$46.2K 0.01%
+20,000
New +$56.5K
KVUE icon
34
Kenvue
KVUE
$38.4B
$26.4K 0.01%
+1,000
New +$26.1K
AMGN icon
35
Amgen
AMGN
$213B
– –
-30,000
Closed -$7.25M
ASND icon
36
Ascendis Pharma A/S
ASND
$16.5B
– –
-20,000
Closed -$2.14M
FENC icon
37
Fennec Pharmaceuticals
FENC
$361M
– –
-149,200
Closed -$1.24M
ICUI icon
38
ICU Medical
ICUI
$4.13B
– –
-3,000
Closed -$495K
MXCT icon
39
MaxCyte
MXCT
$105M
– –
-100,000
Closed -$495K
NEOG icon
40
Neogen
NEOG
$2.08B
– –
-100,000
Closed -$1.85M
PCRX icon
41
Pacira BioSciences
PCRX
$1.06B
– –
-10,000
Closed -$408K
PPA icon
42
CALL
Invesco Aerospace & Defense ETF
PPA
$8.34B
– –
-100,000
Closed -$14.5M
QQQ icon
43
PUT
Invesco QQQ Trust
QQQ
$441B
– –
-250,000
Closed -$80.2M
SEM
44
DELISTED
Select Medical
SEM
– –
-46,400
Closed -$646K
TDOC icon
45
PUT
Teladoc Health
TDOC
$1.59B
– –
-150,000
Closed -$3.88M
THC icon
46
CALL
Tenet Healthcare
THC
$21.7B
– –
-50,000
Closed -$2.97M
UTHR icon
47
United Therapeutics
UTHR
$26.4B
– –
-6,000
Closed -$1.34M
NSTG
48
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-25,000
Closed -$248K
SLGCW
49
DELISTED
SomaLogic, Inc. Warrant
SLGCW
– –
-20,000
Closed -$51K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, Tamarack Advisers held 49 positions worth $324M, up 18% from $274M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Tamarack Advisers deployed $37M of net new capital in Q2 2023, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 75,000 shares worth $6.5M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 48% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was DocGo, an estimated $4.17M trimmed.

  • Tamarack Advisers's largest Q2 2023 buy was BioMarin Pharmaceuticals: 75,000 shares worth $6.5M.
  • Tamarack Advisers added most to McKesson in Q2 2023, an estimated $4.23M increase.
  • Tamarack Advisers's biggest Q2 2023 reduction was DocGo, cutting an estimated $4.17M.
  • Tamarack Advisers fully exited Amgen in Q2 2023, selling an estimated $7.25M.
  • Tamarack Advisers's ten largest holdings make up 80% of its $324M portfolio in Q2 2023.
  • Tamarack Advisers opened 10 new positions and closed 15 in Q2 2023.
  • Tamarack Advisers's portfolio value rose 18% quarter-over-quarter to $324M.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.